Combination Chemotherapy with Cisplatin and Vinorelbine in Patients with Non-Small-Cell Lung Cancer.
- Author:
Kee Won KIM
1
;
Suk Young PARK
;
Ji Won SUHR
;
Seung Joon KIM
;
Dong Hoen YANG
;
Eun Hee LEE
;
Kyung Shick LEE
Author Information
1. Departments of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Non-small-cell lung cancer;
Chemotherapy;
Vinorelbine;
Cisplatin
- MeSH:
Cisplatin*;
Constipation;
Drug Therapy;
Drug Therapy, Combination*;
Humans;
Lung Neoplasms*;
Lung*;
Thrombophlebitis
- From:Journal of the Korean Cancer Association
2000;32(5):911-917
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To determine the therapeutic effect and toxicities of cisplatin and vinorelbine combination chemotherapy in patients with inoperable non-small-cell lung cancer. MATERIALS AND METHODS: Between Jan 1998 and Dec 1999, 28 patients with inoperable non- small-cell lung cancer were treated with cisplatin and vinorelbine combination chemotherapy as induction treatment. A combination of vinorelbine 25 mg/m2 day 1,8 and cisplatin 60 mg/m2 day 1 were given and repeated every 3 weeks. Then we assessed response and toxicity according to WHO grades. RESULTS: According to response criteria, there were 1 complete response, 12 partial response (42.9%), 12 stable disease (42.9%), and 3 progression (10.7%). The median survival was 12 months. According to toxicity grades, 24 grade 3 myelosuppression (24.7%), 12 grade 4 myelo suppression (10.7%), 6 grade 3 and 4 constipation (6.1%), and mild 7 (7.2%) thrombophlebitis were experienced in evaluable 97 cycles. There was no other clinically severe toxicity. CONCLUSION: These results suggest that combination chemotherapy with cisplatin and vinorelbine in patients with inoperable non-small-cell lung cancer was effective and safe.
